TTP273 / vTv Therapeutics - LARVOL DELTA

Huadong Medicine...terminates oral GLP-1 project cooperation [Google translation] (bydrug.pharmcube.com) - "In addition, Huadong Medicine also issued an announcement, announcing that its subsidiary Sino-US Huadong has recently signed a project termination confirmation letter with its US partner vTv Therapeutics. Sino-US Huadong has decided to terminate the subsequent research and development of the oral small molecule GLP-1 receptor agonist TTP273 project."

Commercial • Discontinued • Metabolic Disorders

Effects of the Oral, Small Molecule GLP-1R Agonist TTP273 on Patients with Stage 2 Hypertension: Results from a Post Hoc Analysis of the Phase 2 Logra Study (ADA 2019) - "No significant changes in DBP or pulse rate were observed with either active group compared to placebo.Results from this post hoc analysis suggest that TTP273 could provide an additional benefit of reducing SBP, in line with other GLP-1R agonists. Unlike other GLP-1R agonists, these effects occurred without the side effects of nausea and vomiting."

Clinical • P2 data • Retrospective data